ClinicalTrials.gg
Not yet recruitingNCT07737600Updated Aug 4, 2026

A Study of MRG007 Combination Therapy for Advanced Colorectal Cancer

A Phase 1/2 interventional study of MRG007 and 5-Fluorouracil / Leucovorin Calcium in Advanced Colorectal Cancer, sponsored by Lepu Biopharma Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-04.

Sponsored by Lepu Biopharma Co., Ltd. · Phase 1/2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
316
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,139 studies in Colorectal Neoplasms with a site in China — 529 open to participants now, 606 under way, 67 of them phase 3. Colorectal Neoplasms · China.

Planned enrollment
156th of 894
316 · median 80
Started
2026
with 117 others
Phase 1/2
95 of 1,139
44 open now
Primary completion
2028-12
later than 533 of 605 live
Registered
1,101st of 1,139
by date

Among the 1,139 studies in Colorectal Neoplasms with a site in China, this one is the 156th largest by planned enrollment of the 894 interventional ones that give a count, is one of 118 that started in 2026, is one of 95 in phase 1/2, reaches primary completion later than 533 of the 605 other live ones, and was the 1,101st registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

529 of the 1,139 studies in Colorectal Neoplasms with a site in China are open now. Recruiting first, the newest first:

524 more — sign in →

All 529 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,139 studies in Colorectal Neoplasms with a site in China, or all of them as a file.
02

Study summary

This is a Phase Ib/II clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of MRG007 combination therapy in patients with advanced colorectal cancer.

03

Conditions studied

  • Advanced Colorectal Cancer

Keywords

  • MRG007
  • Advanced Colorectal Cancer
  • CDH17
  • ADC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Expected survival of ≥ 3 months.
  2. Tumor tissue specimens must be provided for relevant biomarker testing. If archived tissue specimens are unavailable, a new must be performed.
  3. confirmed, unresectable locally advanced or colorectal adenocarcinoma.
  4. At least one according to v1.1 criteria. Measurable lesions should not have received prior radiotherapy; however, measurable lesions located within a prior radiation field or after local therapy may be selected as target lesions if disease progression is confirmed.
  5. (ECOG) performance status score of 0 or 1
  6. Adequate organ function must be demonstrated.
  7. Sexually active males and females of must agree to use highly effective measures from the time of signing the form until 6 months after the last dose of the drug. Females of childbearing potential include premenopausal females and females within 1 year after menopause. Females of childbearing potential must have a negative serum pregnancy test result ≤ 7 days prior to the first dose and before randomization.

Exclusion criteria

Exclusion Criteria:

  1. Trial participants with known deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H).
  2. Trial participants with synchronous or multiple primary .
  3. Residual toxicity ≥ Grade 2 resulting from prior anti-tumor therapy.
  4. Symptomatic central nervous system (CNS) and/or .
  5. History of severe cardiovascular disease.
  6. Cerebrovascular accident, pulmonary embolism, or deep vein thrombosis occurring within 3 months prior to the first dose of the drug; thrombosis associated with implanted venous ports or catheters; or superficial vein thrombosis, except for patients with stable thrombosis after standard anticoagulation therapy. Prophylactic use of low-dose low-molecular-weight heparin is permitted.
  7. Clinically symptomatic moderate or larger volume pleural, ascitic, or pelvic effusions requiring clinical intervention, or clinically symptomatic pericardial effusion.
  8. History of gastrointestinal perforation and/or fistula within 6 months prior to the first dose of the investigational drug that has not healed following surgical treatment; risk of bowel obstruction or bowel perforation; extensive bowel resection; poorly controlled Crohn's disease, ulcerative colitis, or other gastrointestinal or inflammatory diseases; presence of pyloric obstruction and/or persistent recurrent vomiting.
  9. Active chronic , active , or (HIV) infection.
  10. to any component or of MRG007, or known ≥ Grade 3 hypersensitivity to other prior anti-CDH17 antibodies or other monoclonal antibodies.
  11. Body weight loss ≥ 10% during the screening period. Any severe and/or uncontrolled systemic disease that, in the opinion of the investigator and the sponsor, renders the participant unsuitable for participation in this study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
316 participants (estimated)

Study arms

  • Experimental
    MRG007 + 5-Fluorouracil / Leucovorin Calcium + Bevacizumab

    Drug: MRG007 · Drug: 5-Fluorouracil / Leucovorin Calcium · Drug: Bevacizumab

  • Experimental
    MRG007 + 5-Fluorouracil / Leucovorin Calcium + Oxaliplatin + Bevacizumab

    Drug: MRG007 · Drug: 5-Fluorouracil / Leucovorin Calcium · Drug: Bevacizumab · Drug: Oxaliplatin

  • Experimental
    MRG007 + 5-Fluorouracil / Leucovorin Calcium + Oxaliplatin + PD-1/VEGF antibody

    Drug: MRG007 · Drug: 5-Fluorouracil / Leucovorin Calcium · Drug: Oxaliplatin · Drug: PD-1/VEGF antibody

  • Experimental
    MRG007 + Capecitabine + Oxaliplatin + Bevacizumab

    Drug: MRG007 · Drug: Bevacizumab · Drug: Oxaliplatin · Drug: Capecitabine

Interventions

  • DrugMRG007

    MRG007 will be administrated as specified in the protocol.

  • Drug5-Fluorouracil / Leucovorin Calcium

    Drug pages: FluorouracilStudies of FluorouracilFluorouracil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · LeucovorinStudies of LeucovorinLeucovorin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    5-Fluorouracil / Leucovorin Calcium will be administrated as specified in the protocol.

  • Bevacizumab will be administrated as specified in the protocol.

  • Oxaliplatin will be administrated as specified in the protocol.

  • DrugPD-1/VEGF antibody

    PD-1/VEGF antibody will be administrated as specified in the protocol.

  • Capecitabine will be administrated as specified in the protocol.

06

What researchers measure

Primary outcomes

  1. Dose Limiting Toxicity (DLT)

    Time frame: From the first dose to 30 days after the last dose

  2. Serious Adverse Events (SAEs)

    Time frame: From the first dose to 30 days after the last dose

  3. Adverse Event (AE)

    Time frame: From the first dose to 30 days after the last dose

  4. Recommended Phase 2 Dose(RP2D) and/or Maximum Tolerated Dose (MTD)

    Time frame: From the first dose to 30 days after the last dose

  5. Objective Response Rate (ORR)

    Time frame: Assessments will be performed every 6 weeks (± 7 days) following the first dose.

Secondary outcomes

  1. Serum Concentration

    Serum Concentration of ADC, TAb, free payload will be measured.

    Time frame: up to 2 years

  2. Anti-Drug Antibody (ADA)

    The proportion of patients with positive ADA results.

    Time frame: up to 2 years

  3. Neutralizing antibody (NAb)

    The proportion of patients with positive NAb results.

    Time frame: up to 2 years

  4. Duration of Response (DOR)

    Time frame: Through study completion, an average 2 years

  5. Disease Control Rate (DCR)

    Time frame: Through study completion, an average 2 years

  6. Progression-Free Survival (PFS)

    Time frame: Through study completion, an average 2 years

  7. Overall Survival (OS)

    Time frame: Through study completion, an average 2 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Dec 2028, 28 months later.

Of 159 industry-sponsored phase 1/2 interventional studies under Colorectal Neoplasms, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 82. This study's planned 28 months is below that.

Counting every sponsor, half of 261 studies reached it within 59 months; a quarter within 36 and three quarters within 87.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2026
First posted
Jul 30, 2026
StartEst.
Aug 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Aug 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07737600
Lead sponsor
Lepu Biopharma Co., Ltd.
Responsible party
Sponsor
First posted
Jul 30, 2026
Start date
Aug 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Aug 4, 2026

Study contacts

Program Director
Contact
ra_bj@lepubiopharma.com
86-21- 67680899

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion